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Structural basis for cooperativity of human
monoclonal antibodies to meningococcal factor H-
binding protein
Ilaria Peschiera1, Maria Giuliani2, Fabiola Giusti2, Roberto Melero1, Eugenio Paccagnini 3,
Danilo Donnarumma2, Werner Pansegrau2, José M. Carazo1, Carlos O.S. Sorzano 1, Maria Scarselli2,
Vega Masignani2, Lassi J. Liljeroos4 & Ilaria Ferlenghi2
Monoclonal antibody (mAb) cooperativity is a phenomenon triggered when mAbs couples
promote increased bactericidal killing compared to individual partners. Cooperativity has
been deeply investigated among mAbs elicited by factor H-binding protein (fHbp), a Neisseria
meningitidis surface-exposed lipoprotein and one of the key antigens included in both ser-
ogroup B meningococcus vaccine Bexsero and Trumenba. Here we report the structural and
functional characterization of two cooperative mAbs pairs isolated from Bexsero vaccines.
The 3D electron microscopy structures of the human mAb–fHbp–mAb cooperative com-
plexes indicate that the angle formed between the antigen binding fragments (fAbs) assume
regular angle and that fHbp is able to bind simultaneously and stably the cooperative mAbs
pairs and human factor H (fH) in vitro. These findings shed light on molecular basis of the
antibody-based mechanism of protection driven by simultaneous recognition of the different
epitopes of the fHbp and underline that cooperativity is crucial in vaccine efficacy.
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N eisseria meningitidis is a worldwide etiological agent ofsevere diseases such as meningitis and septicemia. It is agram negative diplococcus colonizing the nasopharynx of
~10% of healthy humans1. Although colonization is a common
event, specific circumstances can lead to a local inflammation and
a migration of the bacteria into the bloodstream resulting in acute
disease, death, or permanent disability1,2. Crucial features in the
steps of colonization, survival, and spreading are the bacterial
strategies evolved to evade the immune system. One of these
mechanisms lies in the capability to downregulate the comple-
ment pathway activation, through the binding of the meningo-
coccal factor H-binding protein (fHbp) to the human factor H
(fH), a soluble inhibitor of the alternative complement pathway3.
FHbp is a surface-exposed lipoprotein of N. meningitidis
expressed at different levels among the strains and genetically
divided in three variants, var.1, var.2, and var.33,4. FHbp binds fH
on the bacterial surface, enabling the pathogen to evade alter-
native complement-mediated killing by the host innate immune
system and to survive in human serum and blood1,5. The
importance of fHbp in preventing meningococcal infection is
reinforced by its presence as recombinant antigen in both vac-
cines against meningococcal serogroup B licensed so far, rLP2086
(in the US; Trumenba, Pfizer) and 4CmenB (in Europe, Canada,
Australia, USA, and Brazil; Bexero, GSK). These vaccines were
licensed based on their capability to elicit complement dependent,
antibody-mediated bactericidal activity as measured by the serum
bactericidal assay using human complement (hSBA)1,3,4. The
ability of specific anti-fHbp human monoclonal antibodies
(mAbs) to interact and augment protective immunity has been
reviewed6, suggesting that nonbactericidal antibodies can coop-
erate and elicit serum bactericidal activity (SBA). Importantly,
several publications focused on the characterization of murine
anti-fHbp mAbs reveal that the majority is not able to be bac-
tericidal alone, but elicited high bactericidal titers when coupled
with another mAb anti-fHbp6–16. More recently, Giuliani et al.17
revealed that protective response mediated by the synergy of
multiple bactericidal epitopes on the fHbp protein was demon-
strated by antibody couples induced by 4CmenB in humans17.
Indeed, the authors showed that couples of nonbactericidal mAbs
simultaneously binding nonoverlapping regions of fHbp are
functional in hSBA17. This result is in agreement with the idea
that the ability of anti-fHbp mAbs to efficiently engage the C1q
relies on the specific steric configuration assumed by the
antibody-antigen complex7,9,10. In this perspective, the model of
the C1 activation through hexameric IgG cluster proposed by
Diebolder et al. supports with structural data this hypothesis18.
Nevertheless, it has been shown that an increased susceptibility of
bacteria to the complement-mediated bactericidal activity results
from inhibition of the fHbp binding to fH13. Despite all the
studies mentioned, the mechanism of cooperativity by which
pairs of mAbs, individually nonbactericidal or showing low
bactericidal activity, become bactericidal only when acting toge-
ther still remains mostly unknown. The present work clarifies the
structural and functional basis of the cooperativity of human
mAbs coupled to an individual antigen using the recombinant
mAbs generated from vaccine elicited antibodies19. Our results
shed light on the mechanism of activation of the complement
pathway by the simultaneous and stable binding of the coop-
erative human mAbs to different epitopes recognized on the
antigen.
Results
Selection of cooperative and noncooperative mAbs. The human
IgG1 mAbs chosen for this study (1A3, 7B10, 1A12, and 2C1)19
possess specific characteristics as described in Giulani et al.17
Briefly, (1) high synergic bactericidal activity on H44/76N.
meningitidis (reference strain expressing fHbp var.1) in the pre-
sence of human serum as complement source17,20; (2) affinity to
recombinant fHbp with dissociation constant (KD) values ranging
from 1.72 E−10 M−1 to 0.9 E−11 M−1; and (3) different epitope
localizations. mAb 1A12 was included in the panel as an example
of a cross-reactive antibody binding to each of the three main
variants of fHbp. A surface plasmon resonance (SPR) assay was
used to discriminate between cooperative mAbs simultaneously
binding fHbp and the noncooperative ones, binding mutually
exclusive (Fig. 1). From data summarized in Supplementary Fig.
1, it is evident that increased SBA titers (as reported by Giuliani
et al.) can be observed only when couples of mAbs can bind stably
and contemporaneously to the same antigen. In the absence of
simultaneous binding, no signal was present on the sensorgrams,
indicating that the epitope recognized by the second mAb was not
available for the binding when the protein was captured by the
first mAb.
In the present study, each pair of selected mAbs is formed by
an N-terminal-epitope-specific and a C-terminal-epitope-specific
antibody. Although all the N-terminal-specific and C-terminal-
specific mAbs were reported to recognize overlapping regions of
their respective targeted domains, some differences were noticed
and guided our selection. N-terminal-specific 7B10 and 1A3 were
characterized by diverse affinities for the N-terminal domain,
while a different degree of antigen specificity differentiates 2C1
and 1A12, with 1A12 able to recognize the C-terminal domains of
all the three fHbp variants, while 2C1 resulted specific for fHbp
variant 1 as described in Giuliani et al.17
EM analysis of cooperative and noncooperative complexes.
Negative stain-transmission electron microscopy (NS-TEM) was
used to visualize the morphology of the complexes formed by the
cooperative mAbs with the fHbp (mAb7B10–fHbp–mAb2C1 and
mAb1A3–fHbp–mAb1A12). These complexes regularly assumed
the same rhomboidal assembly suggesting the formation of a
stable tetrameric complex formed by two molecules of fHbp and
two copies of mAb (Fig. 2a, b). The 2D class averages obtained, by
applying the single-particle reconstruction method on the NS-
TEM images, revealed that in both complexes, the mAbs were
facing each other with the Fc portions pointing out the rhomboid
and binding two molecules of fHbp, such that the two fHbp
molecules are at the opposite corners of the rhomboid (Fig. 2a, b).
Both the cooperative mAb-based complexes showed the Fc por-
tions free to rotate (Supplementary Movie 1) and corresponded to
the fuzzy electron density observed in the 2D classes (Fig. 2a, b).
Moreover, to evaluate the role of the complementary-determining
regions of the cooperative antibodies, the antigen-binding frag-
ments (fAbs) of each mAb have been generated and TEM analysis
performed on the fAbs–fHbp complexes. The corresponding 2D
class averages assumed an overall “V” shaped structure (Fig. 2c)
indicating that the complex was a heterotrimer made by the two
fAbs each attached to its specific epitope of the same fHbp
molecule (Fig. 2c). As expected the comparison of the 2D class
averages of the fAb7B10–fHbp–fAb2C1 complex with the cor-
responding cooperative mAb7B10–fHbp–mAb2C1 complex
revealed that the angle comprised between the different fAbs and
the antigen was identical (~60°) (Supplementary Movie 2), dif-
ferent from the angle value (~74°) measured for the
mAb1A3–fHbp–mAb1A12 complex. NS-TEM analysis applied to
couples of mAbs recognizing the same domain (7B10–1G3 and
1A12–2C1) in presence of the fHbp molecule showed a relevant
degree of heterogeneous structures with a high number of indi-
vidual mAbs and some structurally irregular supramolecular
complexes including rings (Supplementary Fig. 2).
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Structure comparison of two cooperative mAb complexes. As
the two mAb–fHbp–mAb cooperative complexes and the
fAb7B10–fHbp–fAb2C1 complex showed a preferred orientation
on the TEM grids, it was convenient to apply the random conical
tilt (RCT) approach22. Both untilted and tilted pair images were
therefore collected and processed using the RCT protocol
(Fig. 2a–c). The best 3D structures obtained as initial model for
each immune complex were refined using 10,000 untilted particles
generating a map of mAb7B10–fHbp–mAb2C1 with a resolution of
28 Å, a map of mAb1A12–fHbp–mAb1A3 with a resolution of 26 Å
and a map of fAb7B10–fHbp–fAb2C1 at 23Å resolution (FSC=
0.143) (Fig. 2a–c, right panel). In the cooperative complexes the
distances between the two fHbp copies (positioned along the Y-
axis) varied between 217 Å (mAb7B10–fHbp–mAb2C1) and 203 Å
(mAb1A3–fHbp–mAb1A12). On the contrary, the Fc portions were
free to rotate making impossible a detailed measurement (ranging
in average from 250 to 260 Å) (Supplementary Fig. 3D). These
values were in line with the model proposed by Biagini et al.23
where a distance of 300 Å between neighboring fHbp on the bac-
terial surface ensured an efficient C1q engagement. Both fHbp and
mAbs densities are recognizable in the 3D reconstruction of each
mAb–fHbp–mAb complexes (Fig. 2a, b, right panel) with the mAbs
assuming the typical “Y” shape. The 3D reconstruction of the
fAb7B10–fHbp–fAb2C1 complex (Fig. 2c, right panel) showed
typical features, i.e., bilobed shape, of two fAbs attached to the
density of the fHbp present at the vertex of the complex. A manual
rigid-body fitting was performed using the crystallographic coor-
dinates of IgG1 (PDB 1ZHZ) and fHbp (PDB 3VKD) separately
(Supplementary Fig. 3). The coordinates of the fHbp were docked at
the two vertices of the rhomboid architecture, while the coordinates
of each fAb and Fc portions were fitted separately into the mAbs
maps. FAbs were fitted in one of the elongated arms extending at
the two sides of each of the two fHbp molecules. In every individual
cooperative complex, the fAbs assumed a specific rotation along
their Z-axis (Supplementary Fig. 3A–C). The electron density of the
hinge region, corresponding to a flexible polypeptide linker that
associates the fAbs and Fc portions of the antibody, is not clearly
visible due to the low resolution of the maps and high flexibility of
these regions.
The analysis of the antigen–antibody geometrical relationship was
also performed comparing different reference-free 2D class averages
for each complex. Both mAb–fHbp–mAb complexes assumed a
rhomboid shape in which the fAb portions are tightly attached to the
fHbp epitopes and resulted in a fixed geometry corresponding to a
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Fig. 1 SPR binding competition analysis of cooperative and noncooperative fHbp–mAb complexes. The first SPR signal in each plot corresponds to the
capturing of fHbp by the mAb coupled to the chip surface. The injection of the second mAb only produces an additional signal if cooperative couples are
formed. Sensograms were normalized to the fHbp capture level (capture level= 100 RU in all the sensorgrams) to compensate for differences in capture
efficiency on different mAbs. The color code of the second mAb is reported in the legend. a Immobilized mAb1A3. b Immobilized mAb1A12. c Immobilized
mAb7B10. d Immobilized mAb2C1. e Immobilized mAb1G3. The profiles of immobilized mAb1A3 and 1G3 were reported also by Giuliani et al.17
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well-defined intensity in the 2D classes (Supplementary Fig. 4A, B).
Moreover, in the mAb1A3–fHbp–mAb1A12 tetramer (Supplemen-
tary Fig. 4B), one of the mAb has both fAbs capable to rotate by 90°
along their longitudinal axis. These rotations are observed neither in
the mAb7B10–fHbp–mAb2C1 (Supplementary Movie 1) nor in the
fAb7B10–fHbp–fAb2C1 complexes (Supplementary Fig. 4A, C).
Indeed, the fAbs of different mAbs used the fHbp molecule as a
pivot point that they rotate around their Z-axis thus resulting in
fAbs that are viewed from their side (Fig. 2a, central panel) or on
their back (Supplementary Fig. 4)
Epitope mapping of cooperative and noncooperative mAbs.
Absence of cooperative SBA is typically associated to the incap-
ability of mAb pairs to simultaneously bind fHbp. To investigate
if the absence of concurrent binding is caused by overlapping
epitopes or by steric hindrance between mAbs, a fine epitope
mapping by hydrogen deuterium exchange-mass spectrometry
(HDx-MS) was performed. A total of 68 peptides, covering the
100% of fHbp sequence were monitored for their deuterium
incorporation in the presence and absence of the different mAbs.
The difference was considered relevant when the delta in the
averaged value of deuterium incorporation was superior to 1 Da.
MAb1A3 and mAb7B10 presented overlapping epitopes
composed by the segment of amino acids (aa) 2–27, match into
the initial loop of the fHbp var.1, and the segment aa 101–119,
corresponding to a β-strand (Fig. 3a). The epitope recognized by
the mAb1G3 is precisely described in Giuliani et al.24 Briefly, the
epitope is composed by the segment aa 2–27, which is in common
with the other two mAbs, and the segment aa 43–70, equivalent
to a long loop. We speculate that segment 101–119 formed the
epitope recognized by 1A3 and 7B10 while the difference in
deuterium incorporation observed at the N-terminal region 2–27,
could be due to a stabilizing effect following the mAb interaction.
The C-terminal β-barrel domain contained the epitope of the
mAb2C1, which recognized the segment 167–183 corresponding
mainly to a β-strand (Fig. 3b), and of the mAb1A12, as described
by Lopez-Sagaseta et al.20
Collectively, our results provided a fine mapping of both
N-terminal epitopes, recognized by 1A3, 1G3, and 7B10 human
mAbs, and C-terminal epitopes, recognized by 2C1 and 1A12
human mAbs, respectively, and suggested that simultaneous
binding by such mAbs is prevented by the overlapping
localization of their epitopes. Moreover, our analysis evidenced
that distinct loops are targeted at the C-terminal by 1A12 and
2C1 (Fig. 3). In this case the spatial proximity of these two
epitopes appeared to be responsible of a steric hindrance that
prevented their simultaneous binding.
fH binding to the cooperative couples of human mAbs. The
differences in the repertoire of serum bactericidal antibodies
against fHbp found between human or primate and mouse were
previously attributed to the complex formed between fH and
fHbp19. This binding, specific for human and primate fH, was
hypothesized to restrict the available epitopes to fHbp regions
outside the fH binding site19. To investigate the possible inter-
ference of the cooperative couples on the fHbp–fH binding, a
biophysical analysis using SPR techniques was performed. After
capturing fHbp on the sensor chip surface, the fHbp complexes
with 1A3, 1A12, and 7B10 were tested for binding to human fH.
The presence of an additional signal in the three profiles indicated
that 1A3, 1A12, and 7B10 could form a ternary complex with the
fHbp and the human fH (Supplementary Fig. 5A). Complex
stabilities were assessed by determining their koff rate constants
(Table 1). While there is little difference of fH complex stability in
the presence of mAbs 1A3 and 7B10, a notably faster rate of
dissociation was detected in the presence of mAb1A12 (Table 1,
Supplementary Fig. 5B). The next step consisted of performing
the fH binding experiment in the presence of the cooperative
complex already formed at saturating binding level conditions
(Fig. 4). In this experiment, one mAb was coupled to the sensor to
capture fHbp, while the second mAb was applied before the fH
injection. Interestingly, the sensorgrams demonstrated the for-
mation of quaternary complexes with all possible combinations of
cooperative N-terminal and C-terminal targeting mAbs: a third
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Fig. 2 From NS-TEM images to 3D reconstruction of the immune complexes humAb–fHbp–humAb and of the huFab−fHbp−huFab. From left to right, the
images in each panel describe the negative staining micrograph of RCT, untilted series, and representative 2D class averages and the surface views of
the final 3D reconstruction. Blue dotted circles, in the final 3D reconstructions, indicate the mAb position in the complexes, while red dotted circles indicate
the fHbp position. Rotation of the Fc portion of the mAbs is indicated by white arrows in the 2D class averages of the mAbs–fHbp complexes. a Complex
formed by mAb7B10–fHbp–mAb2C1. b Complex formed by mAb1A3–fHbp–mAb1A12. c Complex formed by fAb7B10–fHbp–fAb2C1. The figures were
generated by UCSF Chimera21. Scale bars, 100 nm for micrographs and 100 Å for both the class averages and the EM maps
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Fig. 3 FHbp epitope recognition by HDX-MS. Each recognized epitope is labeled in red in the cartoon structure of the fHbp var.1 (PDB 3KVD). Boxes above
and/or below the fHbp show the differential deuterium incorporation between the fHbp peptides in presence (blue) or absence (red) of mAb. Deuterium
uptake was detected over time course (exposure time) ranging from 30 s to 30min, and the peptide involved in the exchange is indicated by black arrows.
Epitope mapping of cross-reactive mAb 1G3 is shown in Giuliani et al.17 a The conformational epitope recognized by the mAb1A3 is formed by a loop and a
β-sheet segment both located onto the N-terminus part of the fHbp. The same conformational epitope was recognized by the mAb 7B10. b Epitope of the
mAb2C1 is a segment located onto the C-terminus part of the fHbp and it is formed by a β-sheet. c, Epitope mapping of cross-reactive mAb 1A12 is shown
in Lopez-Sagaseta et al.20
Table 1 Dissociation rate constants of ternary and quaternary mAb–fHbp–fH complexes
Immobilized mAb 1A3 1A12 7B10
Ternary complex
koff (s−1)
7.4E−04 1.6E−03 3.2E−04
Second mAb 1A12 (1A3) 2C1 (1A12) 1A3 2C1 1A12 1A3 2C1
Quaternary
complex koff (s−1)
3.5E−04 7.4E−04 6.3E−04 1.8E−03 6.8E−04 4.3E−02 1.1E−04 3.2E−04 2.9E−04
Parentheses indicate where immobilized and second mAb are identical. In these cases, no binding signal for the second mAb was detectable and accordingly no important difference of koff with respect to
the ternary complex was observed
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signal was generated on the baseline of the stable cooperative
complex profile (Fig. 4a–c). Again, complex stabilities were
assessed by determining the koff rate constants. While complexes
involving the immobilized mAbs 1A3 and 7B10 show little dif-
ference in koff rate constants when a second mAb is involved
(Table 1), complexes formed with immobilized mAb 1A12 show
higher variability in presence of a second mAb. In particular, the
quaternary complex involving immobilized mAb 1A12 and cap-
tured 2C1 show considerable lower stability than the ternary
complex with 1A12, while the quaternary complex comprising
1A12 and 1A3 is notably more stable than the ternary complex
with 1A12 alone (Table 1, Fig. 4b).
Discussion
Cooperative bactericidal activity of mAbs is a biological
mechanism that occurs when mAbs, which are individually not or
weakly bactericidal, become bactericidal in combination. The
underlying mechanism is still poorly understood, but plays a
crucial role in mounting antibody-based protection induced by
vaccination. In principle the ability by two different antibodies to
bind simultaneously the same antigen increases the concentration
of antibody Fc portions suitable for C1q recruitment and trig-
gering of the classical complement pathway cascade, which ulti-
mately results in bacterial killing. Beernink et al.6 observed
bactericidal synergy in couples of murine mAbs anti-fHbp where
at least one of the two mAbs was able to inhibit the binding
between the fH and the antigen fHbp6 underlying the importance
of downregulating the alternative pathway in the immune
response against N. meningitidis. However, Vu et al. demon-
strated that cooperative bactericidal activity may occur also
combining mAbs that did not interfere with binding to fH10. The
supposed key role of inhibition of fH binding has been further
challenged by an important study on the human repertoire of
antibodies elicited by fHbp from three human vaccinees, showing
that bactericidal activity was provided also by human vaccine
elicited anti-fHbp mAbs that do not inhibit the fH binding19. All
these lines of evidence suggested that even in the presence of
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Fig. 4 fH binding to cooperative complexes. The sensorgrams report the binding of fH to cooperative mAb–fHbp complexes. The first signal in each
sensorgram corresponds to the capture of fHbp by the mAb coupled to the sensor chip; the presence of a second signal indicates the binding of the second
cooperative mAb to the complex formed by the immobilized mAb and fHbp. Clearly, the second signal is absent when the second mAb is identical to the
immobilized mAb; in these cases the corresponding epitope is already occupied by the immobilized mAb; the third signal demonstrates the binding of fH to
the cooperative complex. Arrows below the time axis of a indicate injection start points for the various components participating in complex formation. The
identity of the second mAb is given by the color code shown in the legend below the figure. a–c show the sensorgram profiles aligned at the fH baseline,
while d–f report only the aligned and normalized fH signals. The mAb immobilized on the chip surface is indicated at the top of each panel
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alternative complement pathway inhibition, the recruitment of
C1q by anti-fHbp antibodies and the consequent activation of the
classical complement pathway9,12,25 can still lead to efficient
bacterial killing7,9,12,26. Overall our results suggest that antigens
able to capture more than one antibody on their surface represent
ideal candidates for a vaccine.
An optimal relative orientation of the two mAbs bound to the
same antigen has been hypothesized as necessary a prerequisite
for the recruitment of C1q9,12,25. In this work we focused
exclusively on IgG1, the subclass known to be the most effective
in the C1q activation27, that were produced as recombinant
proteins using the heavy and light chains of variable regions from
4CMenB vaccine-elicited mAbs.
Our EM analysis, along with SPR data, clearly showed that
cooperative human mAbs could form very stable quaternary
complexes with fHbp. The complex assumed an overall
rhomboid-shaped architecture with two fHbp molecules at two
opposite vertices of the rhomboid and the two cooperative mAbs
at the other two opposite vertices. Interestingly, the two coop-
erative couples of mAbs tested, although assembling into the
same rhomboidal structure, presented different apertures of the
angle formed by the antigen and the two fAbs attached, strictly
related to the epitope position on the specific antigen binding
sites. The geometrical relationship between the fHbp and the
mAbs in the complex was not influenced by the antibody flex-
ibility, as deduced from the 2D reference classes and the 3DEM
maps of mAb–fHbp–mAb and fAb–fHbp–fAb complexes.
Indeed, the angle formed between fHbp and the antibodies was
similar (Fig. 2 and Supplementary Movie 1). Overall these
observations suggest that epitope location is the driving force for
the reciprocal orientation of the mAbs and the crucial feature for
the cooperative phenomenon. It is interesting although to note
that in both cooperative fHbp–mAbs complexes, the Fc portions
are located around the same distance of ~250 Å. This distance is
in line with the one that could be deduced by Mortenset al.
between the globular heads at the opposite sites of C1q28. In a
previous study Malito et al.29 reported that Fc portions of a
couple of cooperative murine mAb bound to fHbp were separated
by a distance of 130 Å, the same that separate two nonadjacent
globular head of C1q in reported EM structure24,28,30. We can
therefore speculate that a common feature among human and
murine IgG cooperative couples bound to fHbp is the capability
to accommodate the Fc in orientations highly adaptable to the
C1q geometry.
The structures determined in the present study refer to free
mAbs-based and fAbs-based complexes in solution, where anti-
bodies can bind fHbp with both their antigen binding sites.
However, we cannot exclude a higher stoichiometric hetero-
genicity when the complexes are formed on the bacterial surface
where the steric hindrance due to the presence of the membrane
and of the other surface expressed proteins might play an
important role. Nevertheless, the cooperative immune complexes
are still able to recruit the C1q in vivo, activating the complement
pathway as demonstrated by the high bactericidal titers reported
in Giuliani et al.17
Interestingly, although Beernink postulated that inhibition of
fH binding to fHbp was necessarily to observe cooperativity
between fHpb-specific mAbs25, subsequent studies indicated that
human mAbs isolated from vaccinees were able to cooperate
despite their incapability to prevent fH binding19.
Accordingly, in this work we demonstrated that binding of
pairs of cooperative antibodies do not prevent the fHbp inter-
action with fH, thanks to a possible spatial reorganization of the
four molecules (mAb–fHbp–mAb–fH) present in the complex29.
Importantly, the high degree of heterogeneity observed by EM
of the noncooperative human mAbs in the presence of fHbp and
the results of the HDx-MS epitope mapping identified the partial
epitopes overlapping or the steric hindrance of the mAb mole-
cules as the main causes of the absence of complex formation.
Taken together these data underline the fundamental role played
by the epitope location in the mechanism of cooperative anti-
fHbp mAbs activation.
Moreover, the identification of the amino acid residues
affecting the location of the epitope could help in designing new
vaccine candidates able to engage higher numbers of human
mAbs7,9.
To our knowledge this is the first experimentally determined
structure of cooperative vaccine elicited human mAbs in complex
with the bacterial antigen fHbp which provides insights on the
epitope protective properties. Our data underline the important
role played by the synergistic mechanism between protective
mAbs that recognize different epitopes present on the same
protein antigen. The antibodies cooperativity together with the
target antigen density on the bacterial surface23 are fundamental
requirements for classical complement pathway activation and
killing. For this reason, the understanding of the mechanism
responsible of the synergic bactericidal activity could be used as a
helpful information to assist the selection of vaccine candidates
by prioritizing molecules able to stably engage more than one
antibody simultaneously.
Methods
Cloning, expression, and purification of the fHbp. The recombinant protein
fHbp var.1 full length (UniProt Q6QCC2) was expressed using the pET-21b
plasmid (Novagen) in the E. coli strain BL21 (DE3) Star (Invitrogen) as previously
published4,31. The purification was already reported9. Briefly, the fHbp growth was
performed inducing the cells with 0.25 mM IPTG for 5 h at 25 °C. The recombinant
protein was purified from the biomass using a sonication protocol followed by
affinity chromatography (HisTrap HP, GE Healthcare) and cationic exchange
chromatography step (HiTrap SP HP, GE healthcare) in 50 mM Tris, pH 8.0
buffer.
Production and purification of human fAbs and mAbs. FAbs and mAbs anti-
fHbp var.1 were produced according to the protocol described in Giuliani et al.17
Briefly, fAbs anti-fHbp var.1 corresponding to the cooperative mAb7B10 and to
mAb2C1 were produced using heavy chain and light chain from immunoglobulin
variable regions isolated from three vaccines. The expression was performed in E.
coli strain Rosetta 2 (Novagen) in Enpresso B medium (Biosilta) and induced with
1 mM IPTG for 24 h at 25 °C. Following biomass harvest, lysis was performed in
CelLytic Express (Sigma-Aldrich) buffer with 10 mM imidazole. The fAbs purified
were obtained centrifuging the lysate at 18000 × g and subsequently using firstly an
affinity chromatography (His Gravity Trap column, GE Healthcare) and secondly
an ion exchange chromatography (HiTrap SP HP, GE Healthcare). To produce
mAbs anti-fHbp var.1, the same heavy chain and light chain were optimized for
mammalian expression and synthetized by GeneArt (Life Technologies), and the
purified DNA products were ligated into pRS5a Igγ1, Igκ, and Igλ expression
vectors (NIBR) containing the CMV proter and ampicillin resistance. The cloning
was performed in E. coli DH5α cells. The recombinant mAbs were transiently
produced using Expi293 cells (Life Technologies) and harvested at 3 and 6 days
after transfection using a centrifugation at 900 × g for 10 min. Purification of mAbs
was performed with protein G beads (GE Healthcare), according to manufacturer’s
protocol and exchanged into PBS buffer.
Selection of human mAbs. Since mAbs able to induce complement mediated
killing of bacteria correlate with resistance to meningococcal meningitis32,33, the
crucial characteristic of the mAbs was low or no bactericidal titer elicited when
tested alone17, but high titer ranging from 512 to 2048 when coupled. The SBA
titers of each mAb and pairs of mAbs were screened to find cooperative and
noncooperative couples on H44/76 N. meningitidis (reference strain expressing
fHbp var.1) using human serum as a complement source as reported by Giuliani
et al.17 As a second criterion, a high affinity of each single mAb to the antigen was
required to form stable complexes that could be characterized in solution without
the use of cross-linking. SPR was used for detecting the parameters of the binding
affinity and only mAbs showing dissociation constant (KD) values ranging from
1.72 E-10 M−1 to 0.9 E-11 M−1 were chosen. The third feature was the epitope
location of each mAb determined by a combined approach of peptide array
technology, peptide scanning analysis, and sequence alignment, as described by
Giuliani et al.17 The noncooperative couples chosen are composed by one mAb
that recognizes only the var.1 and one that recognizes all the three variants of the
protein17.
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Complexes formation and purification. The complexes were generated by incu-
bating the fHbp var.1 and the desired antibody or fAbs in a 1:1 molar ratio, for 1 h
at room temperature and purified using a Superdex 200 Increase 3.2/300 (GE
Healthcare).
SPR for assessing cooperativity. SPR experiments were performed on a BIAcore
T200 instrument (GE Healthcare). HBS-P (10 mM HEPES pH 7.4, 150 mM NaCl,
0.05% v/v Surfactant P20) was used as running buffer. Approximately 1000 RU of
the desired mAb were immobilized on a CM-5 sensor chip using amine coupling
chemistry, followed by injection of the recombinant fHbp var.1 (100 nM at 30 µl/
min for a contact time of 1 min). The second mAb was injected subsequently at the
same concentration and flow rate. Sensorgrams were analyzed using BIAcore T200
Evaluation 1.0 Software.
SPR for competition assay for fH. The cooperative couples tested were
mAb7B10–mAb2C1 and mAb1A3–mAb1A12. The same approach and conditions
used for the discrimination between cooperative and noncooperative couples were
applied. Capturing of fHbp var.1 was performed on the CM-5 sensor chip cova-
lently loaded with mAb1A3, mAb1A12, or mAb7B10, followed by injection of
second mAb to form the cooperative complex. fH was then injected with a con-
centration of 100 nM with a flow rate of 30 µl/min. The sensorgrams were analyzed
as described above.
HDX-MS analysis for epitope mapping. The HDX-MS analysis was performed
according to Giuliani et al.17 Briefly the antibody/antigen complexes were formed
by mixing 54 pmol of the selected antibody to an equimolar amount of recombi-
nant fHbp var.1, incubated for 30 min at room temperature and prepared and
analyzed as previously explained9. A control experiment for each complex was
performed with the antigen alone at the same condition previously described, using
PBS instead of the antibody. The difference was considered considerable when the
delta in the averaged value of deuterium incorporation was superior to 1 Da.
Transmission electron microscopy. Purified complexes were diluted to 0.03mg/ml
in 20 mM Tris, 300 mM NaCl, pH 8 buffer, and 2.5 µl were loaded for 30 s onto a
300 mesh carbon/formvar coated copper grid (Agar Scientific). After Blotting the
excess, the grid was negatively stained with 1% aqueous uranyl acetate for 45 s and
analyzed using a Philips CM200-FEG transmission electron microscope operating
at 200 kV equipped with a TVIPS TemCam-F224HD CCD camera and TVIPS EM-
Menu4, EM tools, and EM-SPC software packages. The micrographs were acquired
at a magnification of 50,000×, corresponding to a pixel size of 3.3 Å/pixel on the
specimen. As the complexes assumed a preferred orientation onto the grid, dataset
of around 2000 untilted images and a set of 25 RCT pairs of images were collected
at −55° and 0° for each sample.
Image analysis and structure generation. The 2D analysis was performed on a
subgroup of 10,000 particles extracted from the untilted dataset and subjected to
2D classification using Scipion-XMIPP3 with a CL2D method34. The 2D analysis
allowed comparing the flexibility of the angle formed by the fAbs and the fHbp
molecule in the different cooperative complexes (Supplementary Fig. 4). The RCT
dataset was used to generate an initial model within Scipion Software35. Briefly,
particles were independently picked from tilted and untilted datasets and tilt pairs
were assigned according to Vilas et al.36 A subset of ~1000 tilt pairs was obtained
and 2D classification was performed on the untilted particles using CL2D. RCT
maps were then generated for each class average using the pairs extracted. The
maps obtained for each immune complex, showing the best structural character-
istic, were refined within Scipion-XMIPP3 projection matching37 using the sub-
group of 10,000 particles extracted from the untilted dataset. The resolution was
calculated at FSC= 0.143 criterion21. Each map was then manually fitted with the
crystallographic coordinates of the immunoglobulin (PDB 1HZH) and of the fHbp
molecule (PDB 3KVD) in Chimera38.
Use of human sample and human data. ClinicalTrials.gov: NCT02305446. The
purpose/aim of this Phase 3b study conducted in Poland was to assess the safety of
a meningococcal group B vaccine and to collect blood donations to be used in
furthering the development of vaccines against N. meningitidis. Healthy adults
from 18 to 50 years of age received two doses of legacy novartis meningococcal
group B vaccine given 2 months apart. Informed consent form was signed by all
subjects.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The EM maps of the cooperative mAb–fHbp–mAb and fAb–fHbp–fAb complexes
reported in this paper have been deposited in the Electron Microscopy Data Bank
(accession no. EMD-4713, EMD-4714, and EMD-4715). Source data for Supplementary
Fig. 3D are available in Supplementary Data 1.
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